NASDAQ ICAD opened at $5.97 on Tuesday. The business has a fifty day moving average price of $6.26. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 2.90. iCAD has a 12-month low of $2.42 and a 12-month high of $7.22. The stock has a market capitalization of $119.04 million, a price-to-earnings ratio of -15.71 and a beta of 1.04.
iCAD (NASDAQ:ICAD) last released its quarterly earnings results on Tuesday, May 7th. The technology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.08. iCAD had a negative net margin of 36.24% and a negative return on equity of 54.45%. The business had revenue of $6.77 million for the quarter, compared to analyst estimates of $6.10 million. On average, analysts forecast that iCAD will post -0.4 EPS for the current year.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Read More: What are municipal bonds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.